<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545675</url>
  </required_header>
  <id_info>
    <org_study_id>031-KOB-0702</org_study_id>
    <nct_id>NCT00545675</nct_id>
  </id_info>
  <brief_title>Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness</brief_title>
  <acronym>SMART-M</acronym>
  <official_title>Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the difference between Abilify with Depakote vs. Placebo with Depakote in
      24-week treatment in patients with remission status after Abilify with Depakote in the 6-week
      study of acute mania in patients with bipolar disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further study details as provided by Korea OIAA
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recurrence of bipolar disorder from randomization</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abilify(aripiprazole) + Depakote(divalproate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Divalproate + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abilify(aripiprazole)</intervention_name>
    <description>Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depakote (divalproate)</intervention_name>
    <description>Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Mania or mixed episode of bipolar disorder according to DSM-IV

          2. Male and female between the age of 18 and 65 (In case of child-bearing women, negative
             pregnancy test results should be confirmed before the administration of the
             investigational drug and appropriate contraception be used. Pregnant and
             breast-feeding women cannot be included)

          3. Patients who can consent to participate in this clinical trial

          4. Patients who understand this trial and comply with all protocol requirements

          5. Patients who fulfill the following remission criteria for bipolar disorder in the two
             consecutive evaluation performed every week at Week 6 of 6-week study and thereafter:

        (Definition of remission: a score less than 12 on the YMRS total score and simultaneously a
        score less than 13 on the MADRS total score)

        Exclusion Criteria:

          1. Patients with the following clinical symptoms diagnosed using DSM-1. Patients with the
             following clinical symptoms diagnosed using DSM-IV:

               -  Delirium, dementia, amnestic or other cognitive disorders

               -  Schizophrenia or schizoaffective disorder

          2. Patients who do not respond to clozapine

          3. Patients who are expected to require the administration of prohibited concomitant
             drugs during the clinical trial period

          4. Patients diagnosed with substance-related disorder according to DSM-IV within the past
             3 months (abuse, intoxication, dependency and/or withdrawal symptoms). The abuse of
             benzodiazepines is included with the exception of caffeine or nicotine.

          5. Patients known to have allergy or hypersensitivity reaction to Abilify(aripiprazole)
             or other quinolinones

          6. Patients at high risk of suicide attempt or with the history of murder or mental
             status test

          7. Patients with the history of neuroleptic malignant syndrome

          8. Patients with the past history which may cause serious adverse events that can affect
             the safety or efficacy evaluation during the clinical trial period

          9. Patients with clinically significantly abnormal laboratory results, vital sign or ECG
             results

         10. Pregnant women or child-bearing women who do not or cannot use appropriate
             contraception

         11. Patients with the history of convulsive disorder

         12. Patients judged to have decreased compliance to the investigational drugs during a
             6-week trial period by an investigator

         13. Patients who commit serious protocol violation during a 6-week trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won-Myong Bahk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Mary's Hospital, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <last_update_submitted>August 10, 2010</last_update_submitted>
  <last_update_submitted_qc>August 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yonghui Jeong, Clinical Research Manager</name_title>
    <organization>Korea Otsuka Pharmaceutical Co.,Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

